How Your Body's Own Peptide LL-37 Stops Bacteria from Building Protective Biofilms

The researchers grew Pseudomonas aeruginosa biofilms in laboratory conditions and tested whether sub-inhibitory concentrations of LL-37 could prevent biofilm formation or disrupt existing ones. They compared LL-37 against several other antimicrobial peptides (indolicidin, CRAMP, polymyxin B, and Bac2A). Microarray gene expression analysis was used to identify which bacterial genes LL-37 affected, followed by targeted studies on bacterial attachment, twitching motility, and quorum sensing pathways.

Bacterial biofilms are a leading cause of chronic, hard-to-treat infections — from wound infections to lung disease in cystic fibrosis patients. Standard antibiotics often fail against biofilms because the dense bacterial communities shield individual cells. This study revealed that LL-37, a peptide our own immune system produces, has a dedicated anti-biofilm function that works at concentrations far below its antimicrobial threshold. This opens the door to developing peptide-based therapies that prevent or break down biofilms without the selective pressure that drives antibiotic resistance.

Biofilm-related infections account for up to 80% of chronic bacterial infections and are notoriously resistant to conventional antibiotics. This research reveals that human host defense peptides have evolved a sophisticated anti-biofilm capability that operates independently of their direct antimicrobial activity. Understanding this mechanism could lead to new therapeutic strategies — using peptides or peptide-mimetics at low, non-toxic doses to prevent biofilm formation in wounds, medical devices, and chronic lung infections.

This was an in vitro study using laboratory biofilm models, which may not fully replicate the complexity of biofilms in living tissue. The study focused on a single bacterial species (P. aeruginosa), so results may not generalize to all biofilm-forming organisms. Human tissue concentrations of LL-37 vary widely depending on location and health status, so the physiological relevance of the tested concentrations needs further validation in vivo.